2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - La Nouvelle C
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

156 Projected cost savings of a prophylactic tocilizumab-enabled outpatient bispecific initiation pathway in multiple myeloma

Amritpal Singh, MD, Jens Hillengass, MD, PhD2, Brian C. Betts, MD3, Marco Davila, MD, PhD4, Hamza Hassan, MD5, Morgan Steiner, PharmD6, James Driscoll II, MD, PhD7, Ehsan Malek, MD8
1 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
2 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
3 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
4 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
5 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 University Hospitals Case Medical Center, Cleveland, Ohio, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States

FDA-approved BCMA×CD3 (teclistamab, elranatamab and linvoseltamab) and GPRC5D×CD3 (talquetamab) bispecific antibodies (BsAb) are effective therapies for relapsed/refractory multiple myeloma (RRMM) but are associated with the risk of cytokine release syndrome (CRS). Across pivotal studies, CRS occurred in 46%–77% of patients (pts) and was predominantly grade 1, with grade 2 CRS in 10%–21% and grade ≥3 CRS in ≤1.5%. Because CRS occurs predominantly during step-up dosing (SUD) and the first full dose, treatment initiation has traditionally required inpatient monitoring, increasing healthcare resource utilization and costs. Emerging evidence demonstrated that prophylactic tocilizumab reduced CRS from 72% to 25%, with no grade ≥3 CRS (MajesTEC-1 prophylactic cohort), enabling outpatient BsAb initiation without compromising efficacy. To our knowledge, the budget impact of this strategy has not been evaluated. We developed a deterministic budget impact model to estimate healthcare costs and inpatient bed-day savings associated with outpatient BsAb initiation at an NCI-designated comprehensive cancer center.

 Methods: We constructed a deterministic budget impact model comparing the current inpatient step-up dosing (SUD) strategy with a prophylactic tocilizumab-enabled outpatient pathway for teclistamab, elranatamab, and talquetamab. Model inputs were derived from 43 consecutive BsAb initiations (April 2024–July 2026). Direct costs included inpatient hospitalization, agent-specific median length of stay (LOS), prophylactic tocilizumab acquisition (whole-vial costing), institutional outpatient reimbursement estimates, and CRS-related readmissions. Base-case inputs included an inpatient cost of $2,600/day; median LOS of 5, 9, and 11 days for elranatamab, teclistamab, and talquetamab, respectively; prophylactic tocilizumab cost of $2,405/pt (80-kg pt; whole-vial biosimilar pricing); institutional outpatient reimbursement estimates (3 visits; approximately $690/visit; $2,069/pt); a 15% CRS-related readmission rate with a 2-day LOS; and 80% outpatient eligibility, conservatively estimated to account for clinical and logistical barriers (e.g., caregiver availability). One-way sensitivity, threshold, and conservative multivariable scenario analyses were performed across prespecified ranges.

 Results: The base-case cohort included 43 BsAb initiations: 10 elranatamab, 6 teclistamab, and 27 talquetamab. The current inpatient strategy required 401 inpatient bed-days (50 for elranatamab, 54 for teclistamab, and 297 for talquetamab) and cost $1,073,865, including $1,042,600 in inpatient costs and $31,265 for rescue tocilizumab administered to 13 pts (3 elranatamab and 10 talquetamab). Total inpatient costs were $13,722 (elranatamab), $23,400 (teclistamab), and $29,491 (talquetamab) per pt, compared with $5,254/pt for the outpatient pathway, yielding per-pt savings of $8,467 (elranatamab), $18,146 (teclistamab), and $24,237 (talquetamab). Applying the outpatient pathway to 34 of 43 pts (80%) reduced projected cohort costs from $1,073,865 to $406,427, generating $667,438 in net savings (62.2% reduction) while avoiding approximately 306 net inpatient bed-days after accounting for expected CRS-related readmissions, corresponding to $2,183 saved per net bed-day avoided. One-way sensitivity analysis identified inpatient bed-day cost, outpatient eligibility, and inpatient LOS as the primary drivers of model outcomes, whereas prophylactic tocilizumab acquisition cost had the least impact. The outpatient pathway remained cost-saving across all one-way sensitivity analyses and under the conservative scenario. Threshold analysis demonstrated break-even prophylactic tocilizumab acquisition costs of $10,872 (elranatamab), $20,551 (teclistamab), and $26,642 (talquetamab), substantially exceeding both biosimilar ($2,405) and reference-product ($3,396) acquisition costs.

 Conclusion: A prophylactic tocilizumab-enabled outpatient BsAb SUD pathway was projected to substantially reduce healthcare costs and reclaim inpatient bed capacity while remaining robust across sensitivity analyses. Savings were driven primarily by avoided inpatient bed-days, with prophylactic tocilizumab acquisition representing a relatively small offsetting cost. These findings support outpatient BsAb initiation as a scalable, cost-saving strategy with the potential to expand treatment capacity and improve patient access. Prospective real-world validation is warranted.

Amritpal Singh, MD: No relevant conflicts of interest to declare.